English deutsch Impressum
Sitemap Disclaimer
Company Product Investor Relations Newsroom Careers Contact
 
WILEX is developing novel cancer therapies
to provide effective and well tolerated treatment
and enhance patients' quality of life.

RENCAREX®

Therapeutic antibody in Phase III development

Annual General Meeting 2008 on 3 June 2008

Current Presentation as of April 2008

1st Quarter report 2008

Latest News
WILEX reports successful first quarter 2008

Annual Report 2007

 

 

 

Meet WILEX!

15.5.2008
Merrill Lynch Biotech-Medtech 1-on-1 Forum in London

17.-22.5.2008
AUA 2008 Annual Meeting in Orlando

Conference list
© 2006 WILEX AG all rights reserved